- Home
- CNC vs PODD Comparison
CNC vs PODD Comparison
Compare CNC & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNC | PODD |
|---|---|---|
| Founded | 1984 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.7B | 22.1B |
| IPO Year | 2001 | 2007 |
Fundamental Metrics
Financial Performance| Metric | CNC | PODD |
|---|---|---|
| Price | $45.91 | $295.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 19 |
| Target Price | $40.69 | ★ $366.58 |
| AVG Volume (30 Days) | ★ 5.8M | 632.9K |
| Earning Date | 02-03-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.45 |
| Revenue | ★ $167,680,000,000.00 | $2,521,800,000.00 |
| Revenue This Year | $32.55 | $32.55 |
| Revenue Next Year | $0.21 | $20.50 |
| P/E Ratio | ★ N/A | $82.16 |
| Revenue Growth | 14.57 | ★ 27.11 |
| 52 Week Low | $25.08 | $230.05 |
| 52 Week High | $66.81 | $354.88 |
Technical Indicators
Market Signals| Indicator | CNC | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 78.87 | 48.62 |
| Support Level | $40.53 | $278.79 |
| Resistance Level | $40.15 | $290.60 |
| Average True Range (ATR) | 1.17 | 6.30 |
| MACD | 0.48 | 1.07 |
| Stochastic Oscillator | 98.87 | 79.44 |
Price Performance
Historical ComparisonAbout CNC Centene Corporation
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.